Treatment of retinal pigment epithelial detachment with antiangiogenic therapy.
OBJECTIVE
Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) associated with occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).


METHODS
Prospective, comparative, nonrandomized pilot study included patients with PED comprising >50% of total lesion in subfoveal location with visual acuity (VA) 20/40-20/400 and lesions either previously untreated or treated only with photodynamic therapy/verteporfin. Seven patients received pegaptanib 0.3 mg intravitreally (IVT); eight received IVT bevacizumab 1.25 mg. Follow-up occurred every 4-6 weeks for 6 months. Reinjection of initial medication occurred if there was intra- or subretinal fluid observed by optical coherence tomography (OCT) or increased PED. Endpoints were mean changes from baseline to month 6 in VA (ETDRS) and foveal thickness.


RESULTS
At baseline, mean VA was lower, and mean foveal thickness was greater in pegaptanib versus bevacizumab-treated patients (36.1 vs 49.5 letters; 470.4 vs 321.1 mum). Mean improvements to month 6 in VA and foveal thickness were greater for pegaptanib (VA: +9.1 vs +7.2 letters; foveal thickness: -88.2 vs -52.9 mum). On average, pegaptanib-treated patients had slower but more sustained improvement in VA and foveal thickness; bevacizumab-treated patients showed rapid improvement with a slow return towards baseline. Both agents were well tolerated.


CONCLUSIONS
Intravitreal injections of pegaptanib or bevacizumab are both efficacious and safe treatments for PED associated with occult CNV secondary to AMD.
Arias
Luis
L
Department of Ophthalmology, Bellvitge University Hospital, Barcelona, Spain. luisarias@telefonica.net
Ophthalmology. 1985 May;92(5):615-27
2409504
Graefes Arch Clin Exp Ophthalmol. 1989;227(6):501-7
2483142
Retina. 1984 Fall-Winter;4(4):205-20
6085179
Retina. 2007 Jun;27(5):523-34
17558312
Cancer Res. 1990 Mar 15;50(6):1774-8
2155059
Am J Ophthalmol. 2001 May;131(5):541-60
11336929
Arch Ophthalmol. 1994 Apr;112(4):465-72
7512332
Ophthalmic Surg Lasers Imaging. 2006 Nov-Dec;37(6):455-61
17152538
Surv Ophthalmol. 2007 May-Jun;52(3):227-43
17472800
Arch Ophthalmol. 1999 Oct;117(10):1329-45
10532441
Endocr Rev. 2004 Aug;25(4):581-611
15294883
Retina. 2007 Jun;27(5):535-40
17558313
Graefes Arch Clin Exp Ophthalmol. 1992;230(1):11-9
1547961
N Engl J Med. 2004 Dec 30;351(27):2805-16
15625332
Ophthalmology. 1986 May;93(5):543-51
2425324
Retina. 2007 Jun;27(5):541-51
17558314
Ophthalmic Surg Lasers Imaging. 2006 Sep-Oct;37(5):358-63
17017194
N Engl J Med. 2006 Oct 5;355(14):1419-31
17021318
Arch Ophthalmol. 2004 Apr;122(4):453-9
15078661
Graefes Arch Clin Exp Ophthalmol. 2002 Jul;240(7):533-8
12136282
Ophthalmology. 1997 May;104(5):761-9
9160020
Eye (Lond). 1991;5 ( Pt 1):1-12
2060656
Am J Ophthalmol. 1973 Jul;76(1):1-18
4717340
Ophthalmology. 1986 Feb;93(2):224-30
2419817
Ophthalmologe. 2008 Feb;105(2):158-64
17653552
N Engl J Med. 2006 Oct 5;355(14):1432-44
17021319
N Engl J Med. 2007 Feb 15;356(7):748-9; author reply 749-50
17310523
Ann Pharmacother. 2007 Apr;41(4):614-25
17355998
Nat Rev Drug Discov. 2006 Feb;5(2):123-32
16518379
Br J Ophthalmol. 1982 Dec;66(12):745-53
6184070
Retina. 2007 Mar;27(3):342-8
17460590
Retina. 2006 Oct;26(8):859-70
17031284
Trans Ophthalmol Soc U K. 1986;105 ( Pt 6):674-82
3310342